FDA grants regular approval to Keytruda-Lenvima combination for endometrial carcinoma

fda grants regular approval to keytruda lenvima combination for endometrial carcinoma

Sumary of FDA grants regular approval to Keytruda-Lenvima combination for endometrial carcinoma:

  • Back to Healio The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
  • The agency had granted accelerated approval to the combination for this indication in September 2019. Continued approval was contingent upon verification and description of clinical benefit.
  • The FDA based the approval on results of the randomized phase 3 KEYNOTE-775/Study 309 trial, which included 697 women with advanced endometrial carcinoma previously treated with at least one prior platinum-based chemotherapy regimen who had disease that was not microsatellite instability-high or mismatch repair deficient.
  • Researchers randomly assigned 346 women to the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) dosed at 200 mg via IV every 3 weeks plus lenvatinib (Lenvima, Eisai) — a multiple receptor tyrosine kinase inhibitor — dosed at 20 mg orally once daily.
  • The other 351 women received investigator’s choice of doxorubicin dosed at 60 mg/m2 every 3 weeks (n = 254) or paclitaxel dosed at 80 mg/m2 weekly in a 3-weeks-on, 1-week-off schedule (n = 97).
  • Patients assigned the pembrolizumab-lenvatinib combination achieved significantly longer PFS (HR = 0.6;
  • The combination also induced a higher objective response rate (30% vs.
  • ” Fatal adverse reactions occurred among 4.7% of women assigned the pembrolizumab-lenvatinib combination.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close